Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/imj.14859 http://scihub22266oqcxt.onion/10.1111/imj.14859 32415723!ä!32415723 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 300.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Intern+Med+J 2020 ; 50 (6): 667-679 Nephropedia Template TP {{tp|p=32415723|t=2020. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic |pdf=|usr=}}{{32415723}} gab.com Text Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic JO: Intern Med J http://www.kidney.de/pget.php?&tw=1&pmid=32415723 #FOAvip The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources. Twit Text FOAVip Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic ????Intern Med J http://www.kidney.de/pget.php?&tw=1&pmid=32415723 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32415723 #FOAvip English Wikipedia <ref>{{Cite pmid|32415723}}</ref> Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic #MMPMID32415723 Di Ciaccio P; McCaughan G; Trotman J; Ho PJ; Cheah CY; Gangatharan S; Wight J; Ku M; Quach H; Gasiorowski R; Polizzotto MN; Prince HM; Mulligan S; Tam CS; Gregory G; Hapgood G; Spencer A; Dickinson M; Latimer M; Johnston A; Armytage T; Lee C; Cochrane T; Berkhahn L; Weinkove R; Doocey R; Harrison SJ; Webber N; Lee HP; Chapman S; Campbell BA; Gibbs SDJ; Hamad N Intern Med J 2020[Jun]; 50 (6): 667-679 PMID32415723show ga The COVID-19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID-19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID-19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID-19, including the use of telehealth, avoidance of non-essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy-associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID-19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID-19 and available local healthcare resources. |*Consensus[MESH] |Australia[MESH] |Betacoronavirus/immunology[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Coronavirus Infections/*epidemiology/immunology/*prevention & control/virology[MESH] |Drug Therapy[MESH] |Guideline Adherence[MESH] |Humans[MESH] |Infection Control/*methods[MESH] |Leukemia, Lymphocytic, Chronic, B-Cell/immunology/*physiopathology/therapy[MESH] |Lymphoma/immunology/*physiopathology/therapy[MESH] |Multiple Myeloma/immunology/*physiopathology/therapy[MESH] |New Zealand[MESH] |Pandemics/*prevention & control[MESH] |Pneumonia, Viral/*epidemiology/immunology/*prevention & control/virology[MESH] |Practice Guidelines as Topic[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH] |Salvage Therapy/methods[MESH]Australian and New Zealand consensus statement on the management of ly(epmc).pdf DeepDyve Pubget Overpricing